Sherri Hernandez, NP
Family · Merrillville, INNPI 1023370954
Payments from drug & device makers
Across 138 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$433
- Merck$165
- Amgen$163
- AstraZeneca$144
- Novo Nordisk$141
- AbbVie$130
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,24299%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 33 | $433 |
| Merck | 11 | $165 |
| Amgen | 10 | $163 |
| AstraZeneca | 10 | $144 |
| Novo Nordisk | 7 | $141 |
| AbbVie | 17 | $130 |
| Boston Scientific | 2 | $100 |
| Bayer | 4 | $92 |
| Scpharmaceuticals Inc. | 3 | $83 |
| Lilly USA, LLC | 4 | $79 |
| Boehringer Ingelheim | 4 | $73 |
| Otsuka America Pharmaceutical, Inc. | 3 | $72 |
| Abbott | 4 | $65 |
| E.r. Squibb & Sons, L.L.C. | 3 | $58 |
| GSK | 3 | $56 |
| Phathom Pharmaceuticals, Inc. | 3 | $54 |
| Johnson & Johnson | 2 | $40 |
| Evoke Pharma, Inc. | 1 | $39 |
| Edwards Lifesciences | 2 | $37 |
| Pfizer | 2 | $32 |
| Philips North America LLC | 1 | $32 |
| Convatec Inc. | 1 | $30 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $19 |
| Shield Therapeutics Inc | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
How this compares
$2,263 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 361 | $349,705 |
| OzempicSemaglutide | 205 | $316,742 |
| EntrestoSacubitril/Valsartan | 267 | $290,783 |
| MounjaroTirzepatide | 96 | $129,695 |
| JardianceEmpagliflozin | 66 | $90,076 |
| RybelsusSemaglutide | 43 | $70,184 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 81 | $61,632 |
| JanuviaSitagliptin Phosphate | 40 | $58,118 |
| TradjentaLinagliptin | 70 | $54,880 |
| FarxigaDapagliflozin Propanediol | 45 | $53,895 |
| XareltoRivaroxaban | 63 | $53,192 |
| VascepaIcosapent Ethyl | 47 | $33,348 |
| Repatha SureclickEvolocumab | 40 | $33,045 |
| VerquvoVericiguat | 25 | $30,920 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 44 | $27,463 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $141 | $386,926248 claims |
| PfizerEliquis | $32 | $349,705361 claims |
| NovartisEntresto | $433 | $290,783267 claims |
| Boehringer IngelheimJardiance, Tradjenta | $73 | $144,955136 claims |
| Lilly USA, LLCMounjaro, Trulicity | $79 | $141,473107 claims |
| AstraZenecaFarxiga, Brilinta, Breztri Aerosphere | $144 | $93,551101 claims |
| MerckJanuvia, Verquvo | $165 | $89,03865 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $56 | $84,472123 claims |
| Johnson & JohnsonXarelto | $40 | $53,19263 claims |
| AbbVieLinzess | $130 | $10,56612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.
Other family in Merrillville
- Mary HoffmanMerrillville$19K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.